Preface

This is Volume II: Antimicrobial Agents of the second edition of Antimicrobial Therapy and Vaccines. Volume I: Microbes was released two years earlier.

Antimicrobial Therapy and Vaccines offers decision-facilitating information – a rare feature in a textbook. Given the exponential growth of both new antibiotics and emerging pathogens, 1700 pages have been added to the second edition of Antimicrobial Therapy and Vaccines in both Volumes I and II (ESun Technologies) as compared to the first edition released in 1998 (Lippincott, Williams, Wilkins). These two textbooks continue with the theme of providing comprehensive information on management and therapy of infectious diseases. The chapters dealing with antimicrobial agents provide detailed information on pharmacology with an emphasis on pharmacodynamics. The strength of these chapters is their link to clinical infectious diseases. This link is enhanced on our companion website described below.

Without this series of textbooks, the best option for the infectious disease clinician and pharmacist requiring current information may be Medline. But the results of Medline searches are erratic, and more importantly, not screened such that references are often of questionable quality and relevance. The experts writing our chapters are authorities in their field and they have screened hundreds of reports and studies for credibility and clinical relevance.

The website www.antimicrobe.org is an integral companion to this textbook and also contains information from the HIV Clinical Manual (Editors: Nina Singh, Robert W. Shafer, Susan Swindells). Purchase of this textbook allows free access to a state-of-the-art website. This website ensures that information on management and therapy is kept up-to-date. A notable advantage of the website is the speed and efficiency at which the information is retrieved; the searches are not based on key words as is the standard approach, but instead uses an innovative search mechanism that is derived from artificial intelligence approaches in medical informatics. Moreover a sophisticated and clever PubMed search incorporated into the website allows readers to retrieve new information that has not yet been reviewed in the textbook. Finally, the search mechanisms in the website are superior to the index in this or any other textbook.

If you have not been given the user name and password for this website, please contact me at vly@pitt.edu.

Numerous individuals have made major contributions to this integrated textbook and website. We would especially like to thank Linda Sadej for her editorial oversight of this massive project, Lixin Liu for her contributions in information science and production of the textbook/website, Yu-Sen Eason Lin for his expertise in website design and information technology, and Chia-Yin Huang for technical support. Kai Yu designed the striking cover of all 3 textbooks in this series: ATV, volume I, ATV volume II, and the HIV Clinical Manual.

If you have any suggestions for improving the textbook and the website, please feel free to contact me. We also request that you point out omissions of organisms or clinical information needed for your practice. Your input will be invaluable in maintaining the relevance of our efforts for your clinical practice.

Victor L. Yu, M.D.
Editor-in-Chief
Contents

SECTION I

Antibacterial Agents .............................. 1

Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Bacterial Infectious Diseases 3
Peggy S. McKinnon, Pharm.D. and Susan L. Davis, Pharm.D.

Aminoglycosides 21
Richard Quintiliani, Jr., M.D., David Nicolau, Pharm.D. and Brian A. Potoski, Pharm.D.

Aztreonam 45
David S. Burgess, Pharm.D. and Ronald G. Hall, Pharm.D.

Beta-lactam and Beta-lactamase Inhibitor Combinations (Amoxicillin/Clavulanic, Ampicillin/Sublactam, Piperacillin/Tazobactam, Ticarcillin/Clavulanic) 55
Peggy S. McKinnon, Pharm.D. and Collin Freeman, Pharm.D.

Carbapenems (Biapenem, Ertapenem, Faropenem, Imipenem, Meropenem, Panipenem) 71
Douglas N. Fish, Pharm.D.

Cephalosporins 89
Blair Capitano, Pharm.D. and Michael B. Kays, Pharm.D.

Chloramphenicol 121
Melinda M. Neuhauser, Pharm.D. and Susan L. Pendland, Pharm.D.

Clindamycin 131
Ronda L. Akins, Pharm.D., Elizabeth A. Coyle, Pharm.D., Matthew E. Levison, M.D. and Jan Verhoef, M.D., Ph.D.

Daptomycin 149
Kerry L. LaPlante, Pharm.D. and Michael J. Rybak, Pharm.D.

Fosfomycin 163
Gary E. Stein, Pharm.D. and Daniel H. Havlichek, Jr., M.D.

Fusidic Acid 171
Keryn J. Christiansen, MBBS

Glycopeptides (Dalbavancin, Oritavancin, Teicoplanin, Vancomycin) 181
N. Virgincarc, M.Sc., M.D. and Alasdair MacGowan, M.D.

Ketolides (Telithromycin, Cethromycin) 201
George G. Zhanen, Ph.D. and Melinda M. Neuhauser, Pharm.D.

Linezolid and Other Oxazolidinones 223
Brian T. Tsuji, Pharm.D., Glenn W. Kaatz, M.D. and Michael J. Rybak, Pharm.D.

Macrolides 243
Lutfiye Mulazimoglu, M.D., Paul M. Tulkens, M.D., Ph.D. and Françoise Van Bambeke, Pharm.D.

Metronidazole 281
Brian J. Barnes, Pharm.D., Kenneth C. Lamp, Pharm.D. and Melinda K. Lacy, Pharm.D.

Mupirocin 293
Suzanne F. Bradley, M.D.

Nitrofurantoin 305
Gary E. Stein, Pharm.D. and Daniel H. Havlichek, Jr. M.D.
Contents

Penicillins 309
Sandra L. Preston, Pharm.D. and
George L. Drusano, M.D.

Quinolones 337
Susan L. Davis, Pharm.D.,
Melinda M. Neuhauser, Pharm.D. and
Peggy S. McKinnon, Pharm.D.

Quinupristin/Dalfopristin 367
Kimberly D. Leuthner, Pharm.D.,
Jeffrey R. Aeschlimann, Pharm.D. and
Michael J. Rybak, Pharm.D.

Rifamycins for Mycobacterial Infections 383
Charles A. Peloquin, Pharm.D. and
Andrew A. Vernon, M.D., M.H.S.

Rifamycins for Nonmycobacterial Infections 403
Rocsanna Namdar, Pharm.D.,
Anne B. Morris, M.D. and
Charles A. Peloquin, Pharm.D.

Sulfonamides 455
Daniel H. Havlichek, Jr., M.D. and
Gary E. Stein, Pharm.D.

Tetracyclines and Analogues 461
Beulah Perdue Sabundayo, Pharm.D., MPH
and Harold C. Standiford, M.D.

Tigecycline 477
David R.P. Guay, Pharm.D.

Trimethoprim and Trimethoprim-
Sulfamethoxazole (Cotrimoxazole) 485
Fred W. Goldstein, M.D. and
Gary E. Stein, Pharm.D.

SECTION II

Antimycobacterial Agents 501
Pharmacokinetic and Pharmacodynamic Issues in
the Treatment of Mycobacterial Infections 503
Eric Nuernberger, M.D. and
Jacques Grosset, M.D.

Cycloserine 517
Charles A. Peloquin, Pharm.D.

Ethambutol 523
Milena L. Lewis, M.D.

Ethionamide 533
Rocsanna Namdar, Pharm.D. and
Charles A. Peloquin, Pharm.D.

Isoniazid (INH) 539
William J. Burman, M.D. and
Charles A. Peloquin, Pharm.D.

Para-Aminosalicylic Acid 551
Charles A. Peloquin, Pharm.D.

Pyrazinamide 559
Leonid Heifets, M.D., Ph.D.

SECTION III

Antifungal Agents 571
Antifungal Agents: In vitro Susceptibility
Testing, Pharmacodynamics, and Prospects for
Combination Therapy 573
Andreas H. Groll, M.D. and
Hedwig Kolve, Pharm.D.

Amphotericin B 591
Astrid M.L. Oude Lashof, M.D. and
Bart-Jan Kullberg, M.D.

Azoles (Clotrimazole, Fluconazole, Itraconazole,
Ketoconazole, Miconazole, Voriconazole) 609
Andreas H. Groll, M.D.,
Hedwig Kolve, Pharm.D. and
Thomas J. Walsh, M.D.

Echinocandins (Caspofungin) 637
Alexander Imhof, M.D. and
Kieren A. Marr, M.D.

Flucytosine 651
Richard H. Drew, Pharm.D. and
John R. Perfect, M.D.
SECTION IV

Antiviral Agents ........................................ 679

Abacavir 681
Patrick G. Clay, Pharm.D. and
Ross G. Hewitt, M.D.

Adefovir 691
Tony Antoniou, Pharm.D.,
Patrick G. Clay, Pharm.D. and
Alice L. Tseng, Pharm.D.

Amantadine, Rimantadine, and Related Agents 705
Frederick G. Hayden, M.D. and
Fred Y. Aoki, M.D.

Cidofovir 731
Patty Fan-Havard, Pharm.D. and
Edward J. Zabawski, Jr., D.O.

Enfuavirtide and Other Fusion Inhibitors 747
Rami Kantor, M.D. and
Gene D. Morse, Pharm.D.

Ganciclovir 757
Judianne C. Slish, Pharm.D.,
Clyde S. Crumpacker and
Tony Antoniou, Pharm.D.

Influenza Neuraminidase Inhibitors (Oseltamivir and Zanamivir) 773
Frederick G. Hayden, M.D. and
Fred Aoki, M.D.

Interferons 791
Marion G. Peters, M.D. and
David J. Quan, Pharm.D.

Lamivudine and Emtricitabine 803
Linda M. Catanzaro, Pharm.D.,
Richard B. Pollard, M.D.,
Robert W. Shafer, M.D.,
Judianne C. Slish, Pharm.D.,
Aesha D. Alkebulan, Pharm.D. and
Gene D. Morse, Pharm.D.

Nonnucleoside Analogues (Delavirdine, Efavirenz, Nevirapine) 817
Courtney V. Fletcher, Pharm.D.,
Michael Para, M.D. and
Susan Swindells, MBBS

Nucleoside Analogues (Acyclovir, Famciclovir, Penciclovir, Valacyclovir) 835
Linda M. Catanzaro, Pharm.D.,
Aesha D. Alkebulan, Pharm.D. and
Gene D. Morse, Pharm.D.

Nucleoside Analog Reverse Transcriptase Inhibitors (Didanosine, Zalcitabine, Zidovudine) 845
Margaret A. Fischl, M.D.,
Linda M. Catanzaro, Pharm.D.,
Robert W. Shafer, M.D. and
Gene D. Morse, Pharm.D.

Protease Inhibitors (Amprenavir, Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir) 865
Linda M. Catanzaro, Pharm.D.,
Angela Kashuba, Pharm.D.,
Amanda H. Corbett, Pharm.D.,
Robert W. Shafer, M.D.,
Ross G. Hewitt, M.D.,
Edward Acosta, Pharm.D. and
Gene D. Morse, Pharm.D.

Ribavirin 909
Ruth E. Berggren, M.D.,
Patrick G. Clay, Pharm.D. and
Juan J. L. Lertora, M.D., Ph.D.
Contents

Stavudine 923  
Linda M. Catanzaro, Pharm.D.,  
Richard B. Pollard, M.D.,  
Robert W. Shafer, M.D.,  
Aesha D. Alkebulan, Pharm.D. and  
Gene D. Morse, Pharm.D.

Tenofovir 935  
Tony Antoniou, Pharm.D.,  
Laura Y. Park-Wyllie, Pharm.D.,  
Alice L. Tseng, Pharm.D. and  
Ross G. Hewitt, M.D.

SECTION V

Antiparasitic Agents ..................................... 947

Pharmacokinetic and Pharmacodynamic Issues in  
the Treatment of Parasitic Infections 949  
Geoffrey Edwards, Ph.D. and  
Sanjeev Krishna, DPhil, FMedSci

4-Aminoquinolines (Amodiaquine, Chloroquine) 961  
Geoffrey Edwards, Ph.D.,  
Patrick G. Bray, Ph.D. and  
Stephen A Ward, Ph.D.

Antimonials (Meglumine antimoniate, Sodium  
stibogluconate) 973  
Robert N. Davidson, M.D., DTM&H and  
Margriet den Boer, Pharm.D.

Artemisinin and Its Derivatives 981  
Kenneth F. Ilett, BPharm., Ph.D. and  
Kevin T. Batty, BPharm., Ph.D.

Atovaquone and Atovaquone-Proguanil 1003  
David B. A. Hutchinson, M.B., B.S., DTM&H and  
Gerri B. Miller, M.S.

Benzimidazoles (Albendazole, Mebendazole,  
Thiabendazole, Triclabendazole) 1021  
Thomas A. Moore, M.D. and  
James McCarthy, M.D.

Benznidazole 1037  
Louis V. Kirchhoff, M.D., M.P.H.

Bithionol 1039  
Joyce-Primo Carpenter, B.Sc. Pharm., M.D.

Diloxanide Furoate 1041  
Joyce-Primo Carpenter, B.Sc. Pharm., M.D.

Efornithine 1043  
Marc Ouellette, Ph.D. and  
Jacques Pépin, M.D.

Emetine and Dehydroemetine 1047  
Joyce Primo-Carpenter, B.Sc. Pharm., M.D.

Folate Antagonists 1049  
William M. Watkins, Ph.D. and  
Peter A. Winstanley, M.D., DTM&H

Furazolidone 1071  
Geoffrey Edwards, Ph.D.

Halofantrine 1075  
Geoffrey Edwards, Ph.D.,  
Patrick G. Bray, Ph.D. and  
Stephen A. Ward, Ph.D.

Iodoquinol 1079  
Joyce Primo-Carpenter, B.Sc. Pharm., M.D.

Ivermectin 1081  
James McCarthy, M.D. and  
Timothy M. E. Davis

Levamisole 1089  
Joyce Primo-Carpenter, B.Sc. Pharm., M.D.

Mefloquine 1091  
Timothy M. E. Davis

Melarsoprol 1105  
Jacques Pépin, M.D. and  
Marc Ouellette, Ph.D.

Metrifonate 1109  
Alexander G.C. Bauer and  
Geoffrey Edwards, Ph.D.
Niclosamide 1113
   Joyce Primo-Carpenter, B.Sc. Pharm., M.D.

Nifurtimox 1115
   Louis V. Kirchhoff, M.D., M.P.H.

Nitazoxanide 1117
   Geoffrey Edwards, Ph.D.

Oxamniquine 1119
   David Overbosch and
   Geoffrey Edwards, Ph.D.

Pentamidine 1123
   Marc Ouellette, Ph.D. and
   Jacques Pépin, M.D.

Piperazine 1127
   James McCarthy, M.D.

Praziquantel 1135
   James McCarthy, M.D. and
   Timothy M. E. Davis

Primaquine 1145
   Peter J. de Vries, M.D., Ph.D. and
   Teunis A. Eggelte, Ph.D.

Pyrantel Pamoate 1161
   Joyce Primo-Carpenter, B.Sc. Pharm., M.D.

Pyrvinium Pamoate 1163
   Joyce Primo-Carpenter, B.Sc. Pharm., M.D.

Quinacrine 1165
   Joyce Primo-Carpenter, B.Sc. Pharm., M.D.

Quinine and Quinidine 1167
   Sanjeev Krishna, DPhil, FMedSci

Suramin 1195
   Jacques Pépin, M.D. and
   Marc Ouellette, Ph.D.